Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CHAMPIONS ONCOLOGY, INC. (CSBR)

Champions Oncology appoints Brian Alexander to board, filling Breitfeld vacancy

Neutral Impact 2 of 5 leadership Written later

Champions Oncology board accepted the resignation of director Dr. Philip Breitfeld on March 24, 2026, and appointed Dr. Brian Alexander to fill the vacancy. The company said the resignation was not due to any disagreement over its operations, policies, or practices.

Key points

  • Board accepted Dr. Philip Breitfeld's resignation as a director on March 24, 2026
  • Dr. Brian Alexander appointed director to fill the resulting vacancy
  • Alexander is CEO of Valo Health and CEO-Partner at Flagship Pioneering, both since November 2024
  • Filing states no related party transactions reportable under Item 404(a) for Alexander

The filing

CompanyCHAMPIONS ONCOLOGY, INC. (CSBR)
Form8-K, current report
Filed with the SECMar 30, 2026, 1:16 PM ET
Accession number0001628280-26-021941

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.